Abstract
Conventionally, monoclonal antibodies (MAbs) are generated by fusing B cells from an immunized animal with myeloma cells from the same species (1). Several murine MAb have already been employed for in vivo diagnosis and therapy, including Ber-H2 which recognizes the human CD30 molecule with high specificity and affinity (2). CD30, a member of the nerve growth factor (NGF) tumor necrosis factor receptor (TNFR) superfamily (3), is strongly expressed on the pathognomonic Hodgkin (H) and Reed-Sternberg (R-S) cells of Hodgkin’s lymphoma (4) and various non-Hodgkin lymphomas of either T- or B-cell type origin (5). Its reaction pattern in normal lymphoid tissue is restricted to a population of blastoid cells located around B-cell follicles and at the rim of germinal centers (2). Consequently, Ber-H2 has been utilized as an immunotoxin by conjugating the antibody to the ribosome-inactivating toxin Saporin to treat four patients with refractory Hodgkin’s lymphoma (6). However, despite remarkable tumor reductions of up to more than 75% were achieved after administration of one single dose of the reagent, patients developed an immune response against both the rodent immunoglobulin and the toxin moiety, precluding further application of the immunotoxin (6). In order to fully preserve the specificity of Ber-H2 and to overcome the aforementioned disadvantages, we have generated a chimeric mouse/human antibody.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Köhler G. and Milstein C. (1975). Continuous culture of fused cells secreting antibody of predefined specifity. Nature 256, 495–497.
Schwarting R., Gerdes J., Durkop H., Falini B., Pileri S., and Stein H. (1989). BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 74, 1678–1689.
Dürkop H., Latza U., Hummel M., Eitelbach F., Seed B., and Stein H. (1992). Molecular cloning and expression of a new member of the nerve growth factor receptor family that is charakteristic for Hodgkin’s disease. Cell 68, 421–427.
Schwab U., Stein H., Gerdes J., Lemke H., Kirchner H., Schaadt M., and Diehl V. (1982). Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature 299, 65–67.
Stein H., Mason D. Y., Gerdes J., O’Connor N., Wainscoat J., Pallesen G., et al. (1985). The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66, 848–858.
Falini B., Bolognesi A., Flenghi L., Tazzari P. L., Broe M. K., Stein H., et al. (1992). 7/14/06 12:15PM. Lancet 339, 1195–1196.
Liu A. Y., Robinson R. R., Hellstrom K. E., Murray E. D., Chang C. P., and Hellstrom I. (1987). Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc. Natl. Acad. Sci. USA 84, 3439–3443.
Hoogenboom H. R., Raus J. C., and Volckaert G. (1990). Cloning and expression of a chimeric antibody directed against the human transferrin receptor. J. Immunol. 144, 3211–3217.
Shitara K., Kuwana Y., Nakamura K., Tokutake Y., Ohta S., Miyaji H., et al. (1993). A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities. Cancer Immunol. Immunother. 36, 373–380.
Krishnan I. S., Hansen H. J., Losman M. J., Goldenberg D. M., and Leung S. O. (1997). Chimerization of Mu-9: a colon-specific antigen-p antibody reactive with gastrointestinal carcinomas. Cancer 80, 2667–2674.
Hanai N., Nakamura K. and Shitara K. (2000). Recombinant antibodies against ganglioside expressed on tumor cells. Cancer Chemother. Pharmacol. 46, S13–S17.
Orlandi R., Gussow D. H., Jones P. T., and Winter G. (1989). Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86, 3833–3837.
Dübel S., Breitling F., Fuchs P., Zewe M., Gotter S., Welschof M., et al. (1994). Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. J. Immunol. Methods 175, 89–95.
Liu A. Y., Robinson R. R., Murray E. D., Ledbetter J. A., Hellstrom I., and Hellstrom K. E. (1987). Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J. Immunol. 139, 3521–3526.
Gillies S. D., Lo K. M., and Wesolowski J. (1989). High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J. Immunol. Methods 125, 191–202.
Weissenhorn W., Weiss E., Schwirzke M., Kaluza B., and Weidle U. H. (1991). Chimerization of antibodies by isolation of rearranged genomic variable regions by the polymerase chain reaction. Gene 106, 273–277.
Kabat E. A. and Wu T. T. (1971). Attempts to locate complementarity determing residues in the variable position of light and heavy chains. Ann. NY Acad. Sci. 190, 382–393.
Kabat E. A., Wu T. T., Reid-Miller M., Perry H. M., and Gottesmann K. (1987) Sequence of proteins of immunological interest. U.S. Department of Health and Human Services, U.S. Government Printing Office, Washington, DC.
Lefranc M. P. (2001). IMGT, the international ImmunoGeneTics database. Nucleic Acids Res. 29, 207–209.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Krauss, J., Förster, H.H., Uchanska-Ziegler, B., Ziegler, A. (2003). Chimerization of a Monoclonal Antibody for Treating Hodgkin's Lymphoma. In: Welschof, M., Krauss, J. (eds) Recombinant Antibodies for Cancer Therapy. Methods in Molecular Biology™, vol 207. Humana Press. https://doi.org/10.1385/1-59259-334-8:63
Download citation
DOI: https://doi.org/10.1385/1-59259-334-8:63
Publisher Name: Humana Press
Print ISBN: 978-0-89603-918-6
Online ISBN: 978-1-59259-334-7
eBook Packages: Springer Protocols